Cipla to form respiratory biosimilars JV with Indian CDMO Kemwell Biopharma
Cipla Limited has entered into a joint venture (JV) agreement with Kemwell Biopharma, a Bengaluru-based biopharma contract development and manufacturing organization (CDMO), for developing, manufacturing, and commercializing biosimilars for global markets.
The Indian pharma company said that a joint venture company will be incorporated in this connection with an objective to foray into the respiratory biosimilars space.
Umang Vohra — Managing Director and Global CEO of Cipla said: “This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership. Guided by our purpose of ‘Caring for life’ our partnership with Kemwell will help serve unmet needs of patients across the globe.”
As per the terms of the agreement, the joint venture will tap the complementary strengths of Cipla and Kemwell Biopharma for end-to-end product development, clinical development, regulatory filings, manufacturing, and commercialization of biopharma products.
Cipla said that its respiratory prowess combined with the expertise of Kemwell Biopharma in biologics will bring the essential products to market at an accelerated pace.
Anurag Bagaria — Chairman and CEO of Kemwell Biopharma said: “We are very excited about combining the strengths of Cipla’s expertise in development and commercialization of respiratory products and Kemwell’s biologics capabilities. Through this JV, we aim to make cost-effective biotherapeutics available to more patients globally.”